CoChat

Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts

Open access
Topp, Monique D., Hartley, Lynne, Cook, Michele, Heong, Valerie, Boehm, Emma, McShane, Lauren, Pyman, Jan, McNally, Orla, Ananda, Sumitra, Harrell, Marisol, Etemadmoghadam, Dariush, Galletta, Laura, Alsop, Kathryn, Mitchell, Gillian, Fox, Stephen B., Kerr, Jeffrey B., Hutt, Karla J., Kaufmann, Scott H., Australian Ovarian Cancer Study, Swisher, Elizabeth M., Bowtell, David D., Wakefield, Matthew J., Scott, Clare L. · 2014 · Molecular Oncology
Cited by 138

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Introduction: Improvement in the ability to target underlying drivers and vulnerabilities of high‐grade serous ovarian cancer (HG‐SOC) requires the development of molecularly annotated pre‐clinical models reflective of clinical responses. Methods: We generated patient‐derived xenografts (PDXs) from consecutive, chemotherapy‐naïve, human HG‐SOC by transplanting fresh human HG‐SOC fragments into subcutaneous and intra‐ovarian bursal sites of NOD/SCID IL2Rγnull recipient mice, completed molecular annotation and assessed platinum sensitivity. Results: The success rate of xenografting was 83%. Of ten HG‐SOC PDXs, all contained mutations in TP53 , two were mutated for BRCA1 , three for BRCA2 , and in two, BRCA1 was methylated. In vivo cisplatin response, determined as platinum sensitive (progression‐free interval ≥100 d, n = 4), resistant (progression‐free interval <100 d, n = 3) or refractory ( n = 3), was largely consistent with patient outcome. Three of four platinum sensitive HG‐SOC PDXs contained DNA repair gene mutations, and the fourth was methylated for BRCA1. In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes ( CCNE1 , LIN28B and/or BCL2 ). Conclusions: Because PDX platinum response reflected clinical outcome, these annotated PDXs will provide a unique model system for preclinical testing of novel therapies for HG‐SOC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.01.008

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Topp, M. D., Hartley, L., Cook, M., Heong, V., Boehm, E., McShane, L., Pyman, J., McNally, O., Ananda, S., Harrell, M., Etemadmoghadam, D., Galletta, L., Alsop, K., Mitchell, G., Fox, S. B., Kerr, J. B., Hutt, K. J., Kaufmann, S. H., Study, A. O. C., Swisher, E. M., Bowtell, D. D., Wakefield, M. J., & Scott, C. L.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-01-24
Volume
8
Issue
3
Pages
656-668
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2020240832
Cited by
138
References
9
FWCI
15.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.